Bloodstream Infections With Candida auris Among Children in Colombia: Clinical Characteristics and Outcomes of 34 Cases.


Journal

Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049

Informations de publication

Date de publication:
26 Mar 2021
Historique:
received: 21 10 2019
accepted: 08 04 2020
pubmed: 7 5 2020
medline: 19 8 2021
entrez: 7 5 2020
Statut: ppublish

Résumé

Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and healthcare-associated outbreaks. Here, we describe 34 cases of pediatric C. auris bloodstream infections (BSIs) identified during July 2014-October 2017 in 2 hospitals in Colombia. We conducted a retrospective review of microbiology records for possible C. auris cases in 2 hospitals in Barranquilla and Cartagena. BSIs that occurred in patients aged <18 years confirmed as C. auris were included in this analysis. We identified 34 children with C. auris BSIs. Twenty-two (65%) patients were male, 21% were aged <28 days, 47% were aged 29-365 days, and 32% were aged >1 year. Underlying conditions included preterm birth (26%), being malnourished (59%), cancer (12%), solid-organ transplant (3%), and renal disease (3%). Eighty-two percent had a central venous catheter (CVC), 82% were on respiratory support, 56% received total parenteral nutrition (TPN), 15% had a surgical procedure, and 9% received hemodialysis. Preinfection inpatient stay was 22 days (interquartile range, 19-33 days), and in-hospital mortality was 41%. Candida auris affects children with a variety of medical conditions including prematurity and malignancy, as well as children with CVCs and those who receive TPN. Mortality was high, with nearly half of patients dying before discharge. However, unlike most other Candida species, C. auris can be transmitted in healthcare settings, as suggested by the close clustering of cases in time at each of the hospitals.Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and healthcare-associated outbreaks. This report describes 34 cases of pediatric C. auris bloodstream infections, identified in two hospitals in Colombia, South America.

Sections du résumé

BACKGROUND BACKGROUND
Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and healthcare-associated outbreaks. Here, we describe 34 cases of pediatric C. auris bloodstream infections (BSIs) identified during July 2014-October 2017 in 2 hospitals in Colombia.
METHODS METHODS
We conducted a retrospective review of microbiology records for possible C. auris cases in 2 hospitals in Barranquilla and Cartagena. BSIs that occurred in patients aged <18 years confirmed as C. auris were included in this analysis.
RESULTS RESULTS
We identified 34 children with C. auris BSIs. Twenty-two (65%) patients were male, 21% were aged <28 days, 47% were aged 29-365 days, and 32% were aged >1 year. Underlying conditions included preterm birth (26%), being malnourished (59%), cancer (12%), solid-organ transplant (3%), and renal disease (3%). Eighty-two percent had a central venous catheter (CVC), 82% were on respiratory support, 56% received total parenteral nutrition (TPN), 15% had a surgical procedure, and 9% received hemodialysis. Preinfection inpatient stay was 22 days (interquartile range, 19-33 days), and in-hospital mortality was 41%.
CONCLUSIONS CONCLUSIONS
Candida auris affects children with a variety of medical conditions including prematurity and malignancy, as well as children with CVCs and those who receive TPN. Mortality was high, with nearly half of patients dying before discharge. However, unlike most other Candida species, C. auris can be transmitted in healthcare settings, as suggested by the close clustering of cases in time at each of the hospitals.Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and healthcare-associated outbreaks. This report describes 34 cases of pediatric C. auris bloodstream infections, identified in two hospitals in Colombia, South America.

Identifiants

pubmed: 32373928
pii: 5831012
doi: 10.1093/jpids/piaa038
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151-154

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Indira Berrio (I)

Medical and Experimental Mycology Group, Corporación para Investigaciones Biológicas, Medellín, Colombia.
Hospital General de Medellín, Medellín, Colombia.

Diego H Caceres (DH)

Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands.

Wilfrido Coronell R (W)

Pediatrician Infectious diseases, PhD Tropical Medicine, Universidad de Cartagena, Cartagena, Colombia.

Soraya Salcedo (S)

Clinical General del Norte, Barranquilla, Colombia.
Universidad Simón Bolivar, Facultad de Ciencias de la Salud, Barranquilla, Colombia.

Laura Mora (L)

Clinical General del Norte, Barranquilla, Colombia.

Adriana Marin (A)

Clinical General del Norte, Barranquilla, Colombia.

Carmen Varón (C)

Fundacion UCI Doña Pilar, Cartagena, Colombia.

Shawn R Lockhart (SR)

Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Patricia Escandón (P)

Instituto Nacional de Salud, Bogota, Colombia.

Elizabeth L Berkow (EL)

Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sandra Rivera (S)

Instituto Nacional de Salud, Bogota, Colombia.

Tom Chiller (T)

Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Snigdha Vallabhaneni (S)

Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH